BTIG Research Issues Pessimistic Forecast for Caris Life Sciences (NASDAQ:CAI) Stock Price

Caris Life Sciences (NASDAQ:CAI) had its price target lowered by investment analysts at BTIG Research from $45.00 to $38.00 in a report released on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock. BTIG Research’s price objective suggests a potential upside of 97.51% from the company’s current price.

Several other analysts also recently commented on the stock. Robert W. Baird lifted their target price on shares of Caris Life Sciences from $26.00 to $28.00 and gave the stock an “outperform” rating in a report on Friday. Evercore set a $38.00 target price on Caris Life Sciences in a research report on Monday, January 5th. Canaccord Genuity Group increased their target price on Caris Life Sciences from $28.00 to $30.00 and gave the stock a “hold” rating in a research note on Monday, December 22nd. Wall Street Zen downgraded Caris Life Sciences from a “buy” rating to a “hold” rating in a research note on Saturday, February 21st. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Caris Life Sciences in a research report on Monday, December 29th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $33.50.

Caris Life Sciences Trading Up 5.1%

Shares of NASDAQ CAI opened at $19.24 on Friday. The company has a debt-to-equity ratio of 0.79, a current ratio of 9.93 and a quick ratio of 9.36. The company has a market cap of $5.43 billion and a P/E ratio of -41.83. Caris Life Sciences has a 12 month low of $17.15 and a 12 month high of $42.50. The business’s 50 day simple moving average is $24.58.

Caris Life Sciences (NASDAQ:CAI) last announced its quarterly earnings results on Thursday, February 26th. The company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.27. During the same period last year, the company posted ($1.73) EPS. The business’s revenue for the quarter was up 125.4% compared to the same quarter last year.

Insider Activity

In other Caris Life Sciences news, insider Luke Thomas Power sold 62,250 shares of the business’s stock in a transaction that occurred on Thursday, December 11th. The shares were sold at an average price of $26.58, for a total transaction of $1,654,605.00. Following the completion of the transaction, the insider directly owned 99,571 shares in the company, valued at $2,646,597.18. The trade was a 38.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 7.80% of the company’s stock.

Institutional Trading of Caris Life Sciences

Several institutional investors and hedge funds have recently modified their holdings of the business. MetLife Investment Management LLC boosted its stake in shares of Caris Life Sciences by 84.0% in the 4th quarter. MetLife Investment Management LLC now owns 1,654 shares of the company’s stock valued at $45,000 after purchasing an additional 755 shares in the last quarter. Global Retirement Partners LLC grew its position in Caris Life Sciences by 99,900.0% during the 4th quarter. Global Retirement Partners LLC now owns 1,000 shares of the company’s stock worth $27,000 after acquiring an additional 999 shares during the last quarter. Olistico Wealth LLC bought a new stake in shares of Caris Life Sciences during the fourth quarter worth about $31,000. Police & Firemen s Retirement System of New Jersey boosted its position in Caris Life Sciences by 15.0% during the 4th quarter. Police & Firemen s Retirement System of New Jersey now owns 11,932 shares of the company’s stock worth $322,000 after buying an additional 1,560 shares during the period. Finally, PEAK6 LLC grew its holdings in Caris Life Sciences by 6.9% during the 4th quarter. PEAK6 LLC now owns 24,800 shares of the company’s stock worth $669,000 after acquiring an additional 1,600 shares during the last quarter.

Caris Life Sciences News Summary

Here are the key news stories impacting Caris Life Sciences this week:

• Positive Sentiment: Q4 earnings and revenue beat—Caris reported GAAP EPS of $0.28 (vs. ~$0.01 consensus) and Q4 revenue of roughly $292–293M, up ~125% year-over-year, showing rapid top-line recovery and a swing to profitability. This beat and margin trend support upward price action. Caris Q4 & 2025 Results
• Positive Sentiment: Interim Achieve 1 readout strongly supports Caris Detect—an internal interim analysis showed whole-genome sequencing (WGS)-based Caris Detect delivered superior sensitivity and specificity versus methylation-based approaches, a key clinical validation ahead of launch that materially de-risks the MCED (multi-cancer early detection) opportunity. This is a major near-term commercial catalyst. Achieve 1 Interim Readout
• Positive Sentiment: Baird initiates coverage with an Outperform—fresh analyst coverage with a positive rating can increase investor interest and provide incremental buy-side demand. Baird Initiates Coverage
• Positive Sentiment: Product innovation—Caris added an AI-powered breast cancer signature to its Caris Molecular Tumor Board Report, enhancing its product set for clinicians and potentially expanding clinical utility and revenue per test. AI Breast Cancer Signature
• Neutral Sentiment: FY‑2026 revenue guidance updated to ~$1.0B–$1.02B, modestly above consensus (~$995.8M); management is guiding continued high growth but investors will watch margin and cadence of MCED roll-out. 2026 Guidance
• Neutral Sentiment: Short-interest data reported is noisy/erroneous in the feed (shows zeros) and is not a meaningful signal; monitor reliable short-interest updates for potential squeezes. (no link)
• Negative Sentiment: Valuation & technical context—despite today’s pop, CAI remains below its 50‑day moving average and off its one‑year high; investors should weigh execution risk of commercializing Caris Detect, regulatory review, and the company’s path to sustained profitability. (background datapoints)

About Caris Life Sciences

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.